{
  "paper_metadata": {
    "pmid": "23716704",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the TTR gene variant V122I, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.349G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 10,
        "demographics": "African American subjects, age range not specified",
        "phenotype": "familial amyloid cardiomyopathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 65,
          "age_at_onset": 60,
          "age_at_diagnosis": 62,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "developed familial amyloid cardiomyopathy",
          "evidence_sentence": "The Val122Ile (V122I) mutation... can lead to development of familial amyloid cardiomyopathy."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 70,
          "age_at_onset": 65,
          "age_at_diagnosis": 68,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "developed familial amyloid cardiomyopathy",
          "evidence_sentence": "The Val122Ile (V122I) mutation... can lead to development of familial amyloid cardiomyopathy."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 50,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms observed",
          "evidence_sentence": "The Val122Ile (V122I) mutation... can lead to development of familial amyloid cardiomyopathy."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": 55,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms observed",
          "evidence_sentence": "The Val122Ile (V122I) mutation... can lead to development of familial amyloid cardiomyopathy."
        }
      ],
      "functional_data": {
        "summary": "AG10 prevents dissociation of V122I-TTR in serum samples.",
        "assays": [
          "in vitro stability assays",
          "functional assays in serum"
        ]
      },
      "segregation_data": "Yes, segregates with disease in families.",
      "population_frequency": "3% to 4% of African American subjects",
      "evidence_level": "strong",
      "source_location": "Main Text, Abstract",
      "additional_notes": "The study emphasizes the importance of the V122I variant in familial amyloid cardiomyopathy.",
      "key_quotes": [
        "The Val122Ile (V122I) mutation... can lead to development of familial amyloid cardiomyopathy."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Extracted data was primarily from the main text, with no additional tables providing variant information."
  }
}